Published in Trends Cardiovasc Med on June 12, 2014
MicroRNA: A new therapeutic strategy for cardiovascular diseases. Trends Cardiovasc Med (2016) 0.81
Cardiac Resynchronization Therapy Outcomes in Type 2 Diabetic Patients: Role of MicroRNA Changes. J Diabetes Res (2015) 0.80
miR-26a inhibits the proliferation of ovarian cancer cells via regulating CDC6 expression. Am J Transl Res (2016) 0.80
MiRNA and TF co-regulatory network analysis for the pathology and recurrence of myocardial infarction. Sci Rep (2015) 0.79
Pulmonary surfactant synthesis in miRNA-26a-1/miRNA-26a-2 double knockout mice generated using the CRISPR/Cas9 system. Am J Transl Res (2017) 0.75
Experimental procedures to identify and validate specific mRNA targets of miRNAs. EXCLI J (2015) 0.75
MicroRNAs as pathophysiological targets: An emerging nexus for personalized medicine in heart failure? Trends Cardiovasc Med (2015) 0.75
Transforming growth factor β: A potential biomarker and therapeutic target of ventricular remodeling. Oncotarget (2017) 0.75
Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev (2004) 16.52
Identification of mammalian microRNA host genes and transcription units. Genome Res (2004) 14.63
Control of stress-dependent cardiac growth and gene expression by a microRNA. Science (2007) 12.08
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10
A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A (2006) 10.09
TGF-beta signaling and the fibrotic response. FASEB J (2004) 9.81
Characterization of microRNA expression profiles in normal human tissues. BMC Genomics (2007) 8.01
Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol (2000) 7.17
MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation (2007) 6.41
Basic and therapeutic aspects of angiogenesis. Cell (2011) 6.40
New ideas about atrial fibrillation 50 years on. Nature (2002) 5.84
Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci (2011) 5.64
Wound healing and its impairment in the diabetic foot. Lancet (2005) 5.63
A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. Dev Cell (2009) 5.28
Genomic analysis of human microRNA transcripts. Proc Natl Acad Sci U S A (2007) 5.20
MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res (2009) 4.88
Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation (1991) 4.65
MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev (2009) 4.62
Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation (1998) 4.54
MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest (2009) 4.39
Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. J Clin Invest (2009) 4.12
Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev (2007) 3.75
Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med (2000) 3.70
Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation (2000) 3.68
MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med (2010) 2.99
Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. Neth Heart J (2007) 2.65
Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation (2011) 2.52
The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo. J Biol Chem (2001) 2.50
Activation of inward rectifier potassium channels accelerates atrial fibrillation in humans: evidence for a reentrant mechanism. Circulation (2006) 2.47
The contribution of ionic currents to changes in refractoriness of human atrial myocytes associated with chronic atrial fibrillation. Cardiovasc Res (2001) 2.41
Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res (1999) 2.37
Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res (2012) 2.28
MicroRNA-181b regulates NF-κB-mediated vascular inflammation. J Clin Invest (2012) 2.24
Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res (1985) 2.23
Small CTD phosphatases function in silencing neuronal gene expression. Science (2005) 2.23
Smooth muscle cell plasticity: fact or fiction? Circ Res (2012) 2.18
Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc Res (2008) 2.05
The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res (2008) 1.94
Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res Cardiol (2012) 1.93
Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci U S A (2012) 1.91
MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein. Nucleic Acids Res (2011) 1.79
Human atrial ion channel and transporter subunit gene-expression remodeling associated with valvular heart disease and atrial fibrillation. Circulation (2005) 1.67
MicroRNA-26a is a novel regulator of vascular smooth muscle cell function. J Cell Physiol (2011) 1.64
Dephosphorylation of the linker regions of Smad1 and Smad2/3 by small C-terminal domain phosphatases has distinct outcomes for bone morphogenetic protein and transforming growth factor-beta pathways. J Biol Chem (2006) 1.63
MicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment. J Clin Invest (2013) 1.55
MicroRNA-26 governs profibrillatory inward-rectifier potassium current changes in atrial fibrillation. J Clin Invest (2013) 1.49
Role of up-regulation of IK1 in action potential shortening associated with atrial fibrillation in humans. Cardiovasc Res (2005) 1.36
Small C-terminal domain phosphatase enhances snail activity through dephosphorylation. J Biol Chem (2008) 1.31
A human 3' miR-499 mutation alters cardiac mRNA targeting and function. Circ Res (2012) 1.29
Elevated miR-499 levels blunt the cardiac stress response. PLoS One (2011) 1.28
Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. J Am Coll Cardiol (2014) 1.20
Effect of Angiotensin-converting enzyme inhibition on one-year mortality and frequency of repeat acute myocardial infarction in patients with acute myocardial infarction. Am J Cardiol (2010) 1.20
MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling. Circ Res (2013) 1.19
Human inward rectifier potassium channels in chronic and postoperative atrial fibrillation. Cardiovasc Res (2002) 1.15
NF-κB mediated miR-26a regulation in cardiac fibrosis. J Cell Physiol (2013) 1.10
Altered microRNAs in bicuspid aortic valve: a comparison between stenotic and insufficient valves. J Heart Valve Dis (2010) 1.10
Atrial ionic remodeling induced by atrial tachycardia in the presence of congestive heart failure. Circulation (2004) 1.09
The immune system and the remodeling infarcted heart: cell biological insights and therapeutic opportunities. J Cardiovasc Pharmacol (2014) 1.08
MiR-133a regulates collagen 1A1: potential role of miR-133a in myocardial fibrosis in angiotensin II-dependent hypertension. J Cell Physiol (2012) 1.07
Role of miR-181 family in regulating vascular inflammation and immunity. Trends Cardiovasc Med (2013) 1.06
Up-regulation of miR-26a promotes apoptosis of hypoxic rat neonatal cardiomyocytes by repressing GSK-3β protein expression. Biochem Biophys Res Commun (2012) 1.02
MicroRNA-208a increases myocardial fibrosis via endoglin in volume overloading heart. PLoS One (2014) 0.94
Digging in the "soil" of the aorta to understand the growth of abdominal aortic aneurysms. Vascular (2009) 0.92
Cardiac fibrosis revisited by microRNA therapeutics. Circulation (2012) 0.92
GATA4 expression is primarily regulated via a miR-26b-dependent post-transcriptional mechanism during cardiac hypertrophy. Cardiovasc Res (2012) 0.90
MicroRNA-26 was decreased in rat cardiac hypertrophy model and may be a promising therapeutic target. J Cardiovasc Pharmacol (2013) 0.90
α-Tomatine suppresses invasion and migration of human non-small cell lung cancer NCI-H460 cells through inactivating FAK/PI3K/Akt signaling pathway and reducing binding activity of NF-κB. Cell Biochem Biophys (2011) 0.87
Inhibition of nuclear factor κB regresses cardiac hypertrophy by modulating the expression of extracellular matrix and adhesion molecules. Free Radic Biol Med (2010) 0.87
Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward. Circ Cardiovasc Qual Outcomes (2012) 0.86
Vein graft failure: current clinical practice and potential for gene therapeutics. Gene Ther (2012) 0.86
MicroRNA and mechanisms of impaired angiogenesis in diabetes mellitus. Circulation (2011) 0.84
Cardiology patient page. Hypertrophic cardiomyopathy: a patient perspective. Circulation (2003) 0.77